Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients
暂无分享,去创建一个
S. Fox | A. Harris | A. Banham | D. Generali | M. Brizzi | A. Bottini | L. Dogliotti | A. Berruti | Gaynor J. Bates | A. Bersiga | S. Bonardi | L. Campo | G. Allevi | M. Milani | S. Aguggini | G. Bates
[1] 本吉 康英. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide , 2008 .
[2] Christophe Benoist,et al. Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. , 2007, Immunity.
[3] Stephen B Fox,et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] K. Jooss,et al. Vascular Endothelial Growth Factor Blockade Reduces Intratumoral Regulatory T Cells and Enhances the Efficacy of a GM-CSF–Secreting Cancer Immunotherapy , 2006, Clinical Cancer Research.
[5] Manuela Milani,et al. Hypoxia-Inducible Factor-1α Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer , 2006, Clinical Cancer Research.
[6] A. Vandenbark,et al. Estrogen‐mediated immunomodulation involves reduced activation of effector T cells, potentiation of treg cells, and enhanced expression of the PD‐1 costimulatory pathway , 2006, Journal of neuroscience research.
[7] S. Fox,et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Shailesh Singh,et al. Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression , 2006, BMC Cancer.
[9] K. Eguchi,et al. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. , 2006, Oncology reports.
[10] Y. Rosenstein,et al. Oestradiol potentiates the suppressive function of human CD4+ CD25+ regulatory T cells by promoting their proliferation , 2006, Immunology.
[11] W. Zou. Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.
[12] M. Sitkovsky,et al. Regulation of immune cells by local-tissue oxygen tension: HIF1α and adenosine receptors , 2005, Nature Reviews Immunology.
[13] M. Huang,et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. , 2005, Cancer research.
[14] J. Schlom,et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. , 2005, Blood.
[15] S. Ziegler,et al. FOXP3 acts as a rheostat of the immune response , 2005, Immunological reviews.
[16] R. Epstein. The CXCL12–CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies , 2004, Nature Reviews Cancer.
[17] J. Body,et al. Ibandronate reduces skeletal morbidity in patients with breast cancer. , 2004, Seminars in oncology.
[18] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[19] R. DuBois,et al. Cyclooxygenase-2: a potential target in breast cancer. , 2004, Seminars in oncology.
[20] S. Saccani,et al. Regulation of the Chemokine Receptor CXCR4 by Hypoxia , 2003, The Journal of experimental medicine.
[21] A. Barqawi,et al. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma , 2003, Cancer.
[22] D. Carbone,et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. , 2003, Blood.
[23] M. Steurer,et al. Increase of regulatory T cells in the peripheral blood of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] T. Nomura,et al. Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .
[25] T. Eberlein,et al. Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.
[26] T. Whiteside,et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] C. June,et al. Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1 , 2002, The Journal of Immunology.
[28] T. Schumacher,et al. Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.
[29] M. Brizzi,et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] M. Brizzi,et al. p 53 but not bcl-2 Immunostaining Is Predictive of Poor Clinical Complete Response to Primary Chemotherapy in Breast Cancer Patients 1 , 2000 .
[31] D. Mullins,et al. Tumor‐induced immune dysfunction: the macrophage connection , 1998, Journal of leukocyte biology.
[32] M. Awwad,et al. Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. , 1990, Immunology.